Boston Therapeutics, Inc.
BTHE · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $5 | $4 | $3 | $3 |
| Enterprise Value | $6 | $5 | $4 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -42.8% | -48.5% | 8.1% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -243.2% | -65.4% | -111.6% | 100% |
| EBITDA | -$0 | -$2 | -$3 | $0 |
| % Margin | -5,112.8% | -11,507.2% | -8,549.5% | 471.7% |
| Net Income | -$1 | -$4 | -$4 | -$2 |
| % Margin | -9,724.5% | -22,622.8% | -11,352.1% | -5,398.8% |
| EPS Diluted | -0.008 | -0.036 | -0.035 | -0.031 |
| % Growth | 77.2% | -2.6% | -14% | – |
| Operating Cash Flow | -$1 | -$1 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$1 | -$1 | -$1 | -$1 |